Class II MHC molecules can use the endogenous pathway of antigen presentation - PubMed (original) (raw)
. 1990 Jan 4;343(6253):74-6.
doi: 10.1038/343074a0.
Affiliations
- PMID: 1967486
- DOI: 10.1038/343074a0
Class II MHC molecules can use the endogenous pathway of antigen presentation
J G Nuchtern et al. Nature. 1990.
Abstract
Models for antigen presentation have divided the world of antigens into two categories, endogenous and exogenous, presented to T cells by class I and class II major histocompatibility complex (MHC) encoded molecules, respectively. Exogenous antigens are though to be taken up into peripheral endosomal compartments where they are processed for binding to class II MHC molecules. Endogenous antigens are either synthesized or efficiently delivered to the cytoplasm before being partially degraded in an as yet undefined way, and complexed with class I MHC molecules. A useful phenotypic distinction between the two pathways has been the sensitivity to weak bases, such as chloroquine, which is a property only of the exogenous pathway. The fungal antibiotic brefeldin A (BFA), which blocks protein transport from the endoplasmic reticulum to the Golgi network, also blocks class I-restricted antigen-presentation, providing us with the corresponding marker of the endogenous pathway. Experiments with influenza virus antigens have supported the view that class II MHC molecules can present exogenous but not endogenous antigen, whereas the observation that class II MHC molecules present measles virus non-membrane antigens by a chloroquine-insensitive pathway suggests that this is not always the case. We show here that influenza A matrix protein can be effectively presented to class II-restricted T cells by two pathways: one of which is chloroquine-sensitive, BFA-insensitive, the other being chloroquine-insensitive and BFA-sensitive. Our results indicate that both class I and class II molecules can complex with antigenic peptides in a pre-Golgi compartment and favour a unified mechanism for MHC-restricted endogenous antigen presentation.
Similar articles
- Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells.
Adorini L, Ullrich SJ, Appella E, Fuchs S. Adorini L, et al. Nature. 1990 Jul 5;346(6279):63-6. doi: 10.1038/346063a0. Nature. 1990. PMID: 2366863 - Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
Pinet V, Malnati MS, Long EO. Pinet V, et al. J Immunol. 1994 May 15;152(10):4852-60. J Immunol. 1994. PMID: 8176208 - Cross-presentation: underlying mechanisms and role in immune surveillance.
Rock KL, Shen L. Rock KL, et al. Immunol Rev. 2005 Oct;207:166-83. doi: 10.1111/j.0105-2896.2005.00301.x. Immunol Rev. 2005. PMID: 16181335 Review. - The HLA system, antigen processing and presentation.
Krensky AM. Krensky AM. Kidney Int Suppl. 1997 Mar;58:S2-7. Kidney Int Suppl. 1997. PMID: 9067934 Review.
Cited by
- The Autophagy Receptor TAX1BP1 (T6BP) improves antigen presentation by MHC-II molecules.
Sarango G, Richetta C, Pereira M, Kumari A, Ghosh M, Bertrand L, Pionneau C, Le Gall M, Grégoire S, Jeger-Madiot R, Rosoy E, Subra F, Delelis O, Faure M, Esclatine A, Graff-Dubois S, Stevanović S, Manoury B, Ramirez BC, Moris A. Sarango G, et al. EMBO Rep. 2022 Dec 6;23(12):e55470. doi: 10.15252/embr.202255470. Epub 2022 Oct 10. EMBO Rep. 2022. PMID: 36215666 Free PMC article. - Integrated Core Proteomics, Subtractive Proteomics, and Immunoinformatics Investigation to Unveil a Potential Multi-Epitope Vaccine against Schistosomiasis.
Rehman A, Ahmad S, Shahid F, Albutti A, Alwashmi ASS, Aljasir MA, Alhumeed N, Qasim M, Ashfaq UA, Tahir Ul Qamar M. Rehman A, et al. Vaccines (Basel). 2021 Jun 16;9(6):658. doi: 10.3390/vaccines9060658. Vaccines (Basel). 2021. PMID: 34208663 Free PMC article. - Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.
Hoffmann PR, Hoffmann FW, Premeaux TA, Fujita T, Soprana E, Panigada M, Chew GM, Richard G, Hindocha P, Menor M, Khadka VS, Deng Y, Moise L, Ndhlovu LC, Siccardi A, Weinberg AD, De Groot AS, Bertino P. Hoffmann PR, et al. Front Oncol. 2019 Aug 2;9:720. doi: 10.3389/fonc.2019.00720. eCollection 2019. Front Oncol. 2019. PMID: 31428586 Free PMC article. - Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
Rakaee M, Busund LR, Jamaly S, Paulsen EE, Richardsen E, Andersen S, Al-Saad S, Bremnes RM, Donnem T, Kilvaer TK. Rakaee M, et al. Neoplasia. 2019 Mar;21(3):282-293. doi: 10.1016/j.neo.2019.01.005. Epub 2019 Feb 10. Neoplasia. 2019. PMID: 30743162 Free PMC article. - Autophagy and Autophagy-Related Proteins in CNS Autoimmunity.
Keller CW, Lünemann JD. Keller CW, et al. Front Immunol. 2017 Feb 27;8:165. doi: 10.3389/fimmu.2017.00165. eCollection 2017. Front Immunol. 2017. PMID: 28289410 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials